Abstract: In one aspect, use of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG) for treating or preventing acute radiation syndrome is provided.

Abstract: In one aspect, methods and compositions are provided for treating a neoplasia such as a solid tumor, the methods and composition comprising a) one or more chemotherapeutic agents such as a checkpoint inhibitor or doxorubicin and/or cyclophosamide; and b) a monoacetyl diacylglycerol compound such as 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG)

Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

Abstract: In one aspect, methods for modulating an inflammatory response are provided comprising administration to a cell or organism a monoacetyl diacylglycerol compound.

Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

Abstract: In one aspect, methods and compositions are provided for treating a neoplasia such as a solid tumor, the methods and composition comprising a) a granulocyte colony-stimulating factor (G-CSF) compound; and b) a monoacetyl diacylglycerol compound such as 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG).

Abstract: Disclosed are methods and compositions for treating diabetes. The composition comprises a monoacetyldiacylglycerol compound of Formula 1 as an active ingredient for treating diabetes. [Formula 1] wherein R1 and R2 are independently a fatty acid residue of 14 to 22 carbon atoms.

Abstract: Disclosed is a method for producing calcobutrol used as an MRI contrast agent. The method comprises the steps of: obtaining butrol represented by chemical formula 2 in the specification by reacting a gadobutrol represented by chemical formula 1 in the specification and a decomplexing agent; and obtaining a calcobutrol represented by chemical Formula 3 in the specification by reacting butrol with calcium ions.

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Abstract: Disclosed are a glycerol derivative that is useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4, IL-6 and so on, or chemokine CXCL8 and reducing migration of HL-60 cell lines, preparation method therefor, and an immunomodulator containing the same as active ingredient. It includes a glycerol derivative represented by Chemical formula 2 or 3 in the specification.

Abstract: Disclosed is a method for producing 1-palmitoyl-2-linoleoyl-3-acetyl glycerol of high purity with high yield by carrying out acetylation of 1-palmitoyl glycerol with acetic anhydride or a mixture of acetic anhydride and acetyl chloride. The method for producing 1-palmitoyl-2-linoleoyl-3-acetyl glycerol comprises the steps of: preparing 1-palmitoyl-3-acetyl glycerol intermediate of Chemical formula 2 in the specification by reacting 1-palmitoyl glycerol of Chemical formula 1 in the specification and an acetylating agent selected from the group consisting of (i) acetic anhydride and (ii) a mixture of acetic anhydride and acetyl chloride; and reacting the 1-palmitoyl-3-acetyl glycerol intermediate and linoleic acid.

Abstract: In one aspect, use of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG) for treating or preventing acute radiation syndrome is provided.

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-?, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

Abstract: Disclosed are a novel diacylglycerol lactone compound for improving immunity and inhibiting infection by promoting neutrophil movement, a preparation method therefor, and an immunostimulator containing same as an active ingredient. The diacyloglycerol lactone compound is represented by chemical formula 1 of the specification. In chemical formula 1, R1 and R2 are respectively N and independently a C2-30 fatty acid group.

Abstract: Disclosed are a novel 1,2-diacylglycerol compound that useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4 and IL-6 or chemokine CXCL8 related to the migration of inflammatory cells, a method for preparing the same, and an immunomodulator containing the same as an active ingredient. The 1,2-diacylglycerol compound is represented by Chemical Formula 2 in the patent specification.

Abstract: In one aspect, use of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG) for treating or preventing acute radiation syndrome is provided.

Abstract: Disclosed is a method for producing calcobutrol used as an MRI contrast agent. The method comprises the steps of: obtaining butrol represented by chemical formula 2 in the specification by reacting a gadobutrol represented by chemical formula 1 in the specification and a decomplexing agent; and obtaining a calcobutrol represented by chemical Formula 3 in the specification by reacting butrol with calcium ions.

Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.